Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 191

1.

HER2-directed therapy for metastatic breast cancer.

Jelovac D, Emens LA.

Oncology (Williston Park). 2013 Mar;27(3):166-75. Review.

2.

Management of patients with HER2-positive metastatic breast cancer: is there an optimal sequence of HER2-directed approaches?

Zelnak AB, Wisinski KB.

Cancer. 2015 Jan 1;121(1):17-24. doi: 10.1002/cncr.28815. Review.

3.

Efficacy and Safety of HER2-Targeted Agents for Breast Cancer with HER2-Overexpression: A Network Meta-Analysis.

Yu Q, Zhu Z, Liu Y, Zhang J, Li K.

PLoS One. 2015 May 20;10(5):e0127404. doi: 10.1371/journal.pone.0127404.

4.

Current and future anti-HER2 therapy in breast cancer.

Vrbic S, Pejcic I, Filipovic S, Kocic B, Vrbic M.

J BUON. 2013 Jan-Mar;18(1):4-16. Review.

PMID:
23613383
5.

Trastuzumab emtansine (T-DM1) for HER2-positive breast cancer.

Boyraz B, Sendur MA, Aksoy S, Babacan T, Roach EC, Kizilarslanoglu MC, Petekkaya I, Altundag K.

Curr Med Res Opin. 2013 Apr;29(4):405-14. doi: 10.1185/03007995.2013.775113. Review.

PMID:
23402224
6.

Recent advances in novel targeted therapies for HER2-positive breast cancer.

Murphy CG, Morris PG.

Anticancer Drugs. 2012 Sep;23(8):765-76. doi: 10.1097/CAD.0b013e328352d292. Review.

PMID:
22824822
7.

Efficacy of HER2-targeted therapy in metastatic breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors.

Nielsen DL, Kümler I, Palshof JA, Andersson M.

Breast. 2013 Feb;22(1):1-12. doi: 10.1016/j.breast.2012.09.008. Review.

PMID:
23084121
8.

[Trastuzumab emtansine (Kadcyla(®)) approval in HER2-positive metastatic breast cancers].

Guerin M, Sabatier R, Gonçalves A.

Bull Cancer. 2015 Apr;102(4):390-7. doi: 10.1016/j.bulcan.2015.02.007. French.

PMID:
25790739
9.

Cardiotoxicity of novel HER2-targeted therapies.

Sendur MA, Aksoy S, Altundag K.

Curr Med Res Opin. 2013 Aug;29(8):1015-24. doi: 10.1185/03007995.2013.807232. Review.

PMID:
23692263
10.

Dual targeting of HER2-positive cancer with trastuzumab emtansine and pertuzumab: critical role for neuregulin blockade in antitumor response to combination therapy.

Phillips GD, Fields CT, Li G, Dowbenko D, Schaefer G, Miller K, Andre F, Burris HA 3rd, Albain KS, Harbeck N, Dieras V, Crivellari D, Fang L, Guardino E, Olsen SR, Crocker LM, Sliwkowski MX.

Clin Cancer Res. 2014 Jan 15;20(2):456-68. doi: 10.1158/1078-0432.CCR-13-0358.

11.

Optimal sequencing of anti-HER2 therapy throughout the continuum of HER2-positive breast cancer: evidence and clinical considerations.

Harbeck N, Wuerstlein R.

Drugs. 2013 Oct;73(15):1665-80. doi: 10.1007/s40265-013-0118-z. Review.

PMID:
24127221
12.

Ado-trastuzumab emtansine (T-DM1): a novel antibody-drug conjugate for the treatment of HER2-positive metastatic breast cancer.

Baron JM, Boster BL, Barnett CM.

J Oncol Pharm Pract. 2015 Apr;21(2):132-42. doi: 10.1177/1078155214527144. Review.

PMID:
24682654
13.

Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer.

Hurvitz SA, Dirix L, Kocsis J, Bianchi GV, Lu J, Vinholes J, Guardino E, Song C, Tong B, Ng V, Chu YW, Perez EA.

J Clin Oncol. 2013 Mar 20;31(9):1157-63. doi: 10.1200/JCO.2012.44.9694. Erratum in: J Clin Oncol. 2013 Aug 10;31(23):2977.

PMID:
23382472
14.

The success story of trastuzumab emtansine, a targeted therapy in HER2-positive breast cancer.

Diéras V, Bachelot T.

Target Oncol. 2014 Jun;9(2):111-22. doi: 10.1007/s11523-013-0287-4. Review.

PMID:
23852665
15.

Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy.

Burris HA 3rd, Rugo HS, Vukelja SJ, Vogel CL, Borson RA, Limentani S, Tan-Chiu E, Krop IE, Michaelson RA, Girish S, Amler L, Zheng M, Chu YW, Klencke B, O'Shaughnessy JA.

J Clin Oncol. 2011 Feb 1;29(4):398-405. doi: 10.1200/JCO.2010.29.5865.

PMID:
21172893
16.

Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases.

Medina PJ, Goodin S.

Clin Ther. 2008 Aug;30(8):1426-47. doi: 10.1016/j.clinthera.2008.08.008. Review.

PMID:
18803986
17.

New HER2-positive targeting agents in clinical practice.

Tolaney S.

Curr Oncol Rep. 2014;16(1):359. doi: 10.1007/s11912-013-0359-8. Review.

PMID:
24442625
18.
19.

Progression and treatment of HER2-positive breast cancer.

Davoli A, Hocevar BA, Brown TL.

Cancer Chemother Pharmacol. 2010 Mar;65(4):611-23. doi: 10.1007/s00280-009-1208-1.

PMID:
20087739
20.

Targeting the HER2 receptor in metastatic breast cancer.

Orphanos G, Kountourakis P.

Hematol Oncol Stem Cell Ther. 2012;5(3):127-37. doi: 10.5144/1658-3876.2012.127. Review.

PMID:
23095788
Items per page

Supplemental Content

Support Center